Compound of formula 1 wherein A is selected from the group consisting of N and CH and wherein M is selected from the group consisting of -CH 2 -, -O-, -NH- and -N(C 1-4 -alkyl)-; R 3 is selected from the group consisting of methyl and ethyl; and wherein R 1 is selected from the group consisting of C 6 - 10 -aryl, Het and Hetaryl; which is optionally further substituted by one, two or three substituents Z, whereby each Z is a substituent selected from the group consisting of -OH, oxo, -CN, halogen, -C 1-6 -alkyl, -O-C 1-6 -alkyl, -C 1-6 -haloalkyl, three- to seven-membered cycloalkyl, Het, Hetaryl, -CO-N(CH 3) 2, -CO-NHCH 3, -CO-NH 2, -(C 1-3 -alkylene)-O-(C 1-3 -alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, -OH, oxo, -C 1-4 -alkyl, -O-C 1-4 -alkyl, -C 1-4 -haloalkyl, -O-(C 1-4 -alkylene)- Het, Het, Hetaryl, -NH 2,-NH(CH 3), -N(CH 3) 2, whereby substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, -OH, halogen and C 1-3 -alkyl, and wherein Het is selected from the group consisting of a five- to six-membered monocyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O, and a nine- to eleven-membered bicyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; Hetaryl is selected from the group consisting of a five- to six-membered monocyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; and a nine- to eleven-membered bicyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; and the pharmaceutically acceptable salts of the aforementioned compounds. A is selected from the group consisting of N and CH and wherein M is selected from the group consisting of -CH 2 -, -O-, -NH- and -N(C 1-4 -alkyl)-; R 3 is selected from the group consisting of methyl and ethyl; and wherein R 1 is selected from the group consisting of C 6 - 10 -aryl, Het and Hetaryl; which is optionally further substituted by one, two or three substituents Z, whereby each Z is a substituent selected from the group consisting of -OH, oxo, -CN, halogen, -C 1-6 -alkyl, -O-C 1-6 -alkyl, -C 1-6 -haloalkyl, three- to seven-membered cycloalkyl, Het, Hetaryl, -CO-N(CH 3) 2, -CO-NHCH 3, -CO-NH 2, -(C 1-3 -alkylene)-O-(C 1-3 -alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, -OH, oxo, -C 1-4 -alkyl, -O-C 1-4 -alkyl, -C 1-4 -haloalkyl, -O-(C 1-4 -alkylene)- Het, Het, Hetaryl, -NH 2,-NH(CH 3), -N(CH 3) 2, whereby substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, -OH, halogen and C 1-3 -alkyl, and wherein Het is selected from the group consisting of a five- to six-membered monocyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O, and a nine- to eleven-membered bicyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; Hetaryl is selected from the group consisting of a five- to six-membered monocyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; and a nine- to eleven-membered bicyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O; and the pharmaceutically acceptable salts of the aforementioned compounds.